Navigation Links
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Date:7/15/2008

Study Reports 92 Percent Response Rate to Combination Treatment

FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride) for Injection plus rituximab. This combination study is one of three studies in patients with NHL that Cephalon submitted in December 2007 to the U.S. Food and Drug Administration requesting approval of TREANDA for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen. TREANDA was approved by the FDA in March 2008 for the treatment of patients with chronic lymphocytic leukemia and is not currently approved for use in NHL.

"A variety of treatment options have been employed in patients with indolent B-cell and mantle cell lymphomas, but resistance to treatment in this patient population often limits effective therapeutic options," said Dr. Charles Morris, Vice President, Worldwide Clinical Research at Cephalon. "Based on what we saw in this study, the combination of TREANDA with rituximab appears to elicit a high rate of durable responses and encouraging progression-free survival."

About the Study

In this multi-center, open-label, single arm, Phase 2 study, 66 patients with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab therapy were treated. Patients received rituximab 375 mg/meter squared intravenously on day one and TREANDA 90 mg/meter squared intravenously on days two and three of a 28-day cycle for up to six cycles. An additional dose of rituximab was given one week before the first cycle and four weeks after the last cycle.

Overall response rate was 92 percent with a complete respon
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
8. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
9. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Sanomedics, Inc. (OTC: SIMH) an international medical technology company ... growing behavioral health sector with the strategic acquisition of ... as a Services (SaaS) provider, specialized in Electronic Health ... centers. "The strategic acquisition of Zen ... health sector where the number of treatment service and ...
(Date:5/26/2015)... , May 26, 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), ... to discuss its financial results for the second quarter of ... at 4:30 p.m. ET on Tuesday, June 2, 2015. The ... fiscal 2015 at the close of the markets on Tuesday, ... 317-6789 or (412) 317-6789 to access the conference call, or ...
(Date:5/26/2015)... 2015 Boehringer Ingelheim today announced that ... once-daily STIOLTO™ RESPIMAT ® (tiotropium bromide and ... a long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. STIOLTO RESPIMAT is ... of COPD. COPD, which includes chronic ...
Breaking Medicine Technology:Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 2Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 3MGC Diagnostics Corporation to Report Second Quarter Fiscal 2015 Financial Results on Tuesday, June 2, 2015 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 3FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 4FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 5FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 6FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 7FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 8FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 9FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 10FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 11FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 12FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 13
... 2012  Vitamin Shoppe, Inc. (NYSE: VSI ), ... products, today announced that it will be participating at ... Retail Conference taking place March 7 - 8, 2012 ... be Mike Archbold, President and COO and Brenda Galgano, ...
... Feb. 29, 2012 Talyst , a leader in ... annual 340B Coalition Winter Conference. The new tool allows health ... The 340B Savings Calculator lets health systems predict their ... "Talyst is dedicated to ensure you receive ...
Cached Medicine Technology:Vitamin Shoppe, Inc. Announces Participation at Investor Conference 2
(Date:5/26/2015)... 26, 2015 The American College of Traditional ... for the Open House/Free Application Day on Wednesday, July 22. ... 4 p.m. and will be held at ACTCM Pioneer Square, ... After checking in, attendees will be greeted with an introduction ... of the campus at 11:45 a.m. Lunch will be served ...
(Date:5/26/2015)... May 26, 2015 Abington is ... Wellness, a physician practice with seven medical professionals, ... the eighth primary-care site in the United States ... medical home by the National Committee for Quality ... primary, preventative and sick care – including routine ...
(Date:5/26/2015)... 26, 2015 It was an evening ... in Colorado. On Wednesday, May 13, The Denver Foundation ... new era of community-based giving with its Annual Celebration, ... in the Making,” the event celebrated the donors, leaders, ... to mobilize resources for good. , “If your organization, ...
(Date:5/26/2015)... Allprovide, the all-natural raw pet food company, today ... now available in three Georgia stores: Pooch-n-Paws in Suwannee; ... Dog Company in Kennesaw. , Allprovide is based out ... climate controlled facility. The fresh ingredients come from select ... food is triple-tested for quality. Unlike most pet foods, ...
(Date:5/26/2015)... Downers Grove, IL (PRWEB) May 26, 2015 ... Worker who is an expert in Neuro-Linguistic Programming, or ... a Master Practitioner in Rapid Resolution Therapy® or RRT®. ... the field of NLP and applied it to specific ... NLP to psychological treatment for over 20 years. ...
Breaking Medicine News(10 mins):Health News:ACTCM to Host Summer Open House 2Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2
... initiatives to encourage healthy eating habits, teens in middle ... 1999, a new study reveals.// And the situation only ... vegetable intake is important for the prevention of future ... Larson, M.P.H. “So it’s important to know whether intakes ...
... recent study by a Saint Louis University researcher confirms findings ... of a gene that causes them to metabolize food// differently, ... ,Edward Weiss, Ph.D., assistant professor of nutrition and dietetics ... looked at a relatively common version of a gene called ...
... by biochemists at the University of California, San Diego ... which inflammation can promote cancer. The findings// may provide ... ,The study shows that what scientists thought were two ... cells’ response to dangers such as invading organisms—are actually ...
... has shown conclusively that a neuropeptide, melanin concentrating hormone ... role in// increasing appetite in people, plays a role ... secretion of insulin. This finding has the potential to ... stimulate the production of insulin-producing beta cells in the ...
... simple scoring system for use by physicians predicts early risk ... known as TIA and also called// a "mini-stroke," according to ... every year in the United States and about 70,000 in ... by temporary reduction in blood and oxygen supply to part ...
... range from the very serious Fetal Alcohol Syndrome to ... Disorders. The timing of alcohol consumption, its frequency, the ... elements of identifying risk. A new survey has found ... consumed alcohol during the three months before pregnancy; nearly ...
Cached Medicine News:Health News:Today’s Teens Slacking on Fruit, Veggie Intak 2Health News:Molecular Link Between Inflammation and Cancer Discovered 2Health News:Molecular Link Between Inflammation and Cancer Discovered 3Health News:Role of Appetite Hormone MCH in Insulin Production Revealed 2Health News:New Tool Improves Prediction of Stroke Risk 2Health News:Risk Factors of Drinking Before, and During, Pregnancy 2
... In 2000, Applied Biosystems introduced ... I S M 3100 Genetic Analyzer.,Now ... instrument is available in our new ... for low- to-medium-throughput laboratory needs, the ...
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
... kit uses proteins produced with recombinant technology, that ... which are capable of detecting the different types ... are proteins with amino acid sequences repeated in ... the acute phase of the infection, it reacts ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Medicine Products: